Alkem Laboratories releases Q4FY26 and FY26 earnings call audio
Alkem Laboratories Limited has released the audio recording of its Q4FY26 and FY26 earnings conference call on its website. The disclosure complies with SEBI regulations and was signed by Manish Narang, President – Legal, Company Secretary & Compliance Officer. The recording is accessible to investors via the company's investor relations portal.
*this image is generated using AI for illustrative purposes only.
Alkem Laboratories Limited has released the audio recording of its Q4FY26 and FY26 earnings conference call. The recording is now available for investors and shareholders on the company’s official website. This disclosure ensures that all market participants have equal access to the management's commentary on the financial performance for the reported periods.
The filing was submitted to the stock exchanges in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was addressed to the Corporate Relationship Departments of BSE Limited and National Stock Exchange of India Limited. The company’s scrip is traded under the code 539523 on the BSE and the symbol ALKEM on the NSE.
Manish Narang, President – Legal, Company Secretary & Compliance Officer, signed the disclosure on behalf of Alkem Laboratories Limited . The document confirmed that the audio file has been uploaded to the dedicated investors section of the corporate portal. The move aligns with standard regulatory practices for post-results transparency.
| Exchange | Entity | Identifier |
|---|---|---|
| BSE Limited | BSE Limited | 539523 |
| National Stock Exchange of India Limited | ALKEM | ALKEM |
The earnings call provides insights into the operational and financial results for the fourth quarter and the full financial year ending March 31, 2026. Stakeholders can review the discussion to understand the factors driving the company's performance during these periods.
Historical Stock Returns for Alkem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.85% | +1.13% | +2.88% | -3.31% | +4.41% | +87.36% |
What are the key growth drivers Alkem management anticipates for the upcoming fiscal year following the FY26 results?
How might the company's capital allocation strategy shift based on the financial performance discussed in the call?
What impact could recent regulatory changes in the pharmaceutical sector have on Alkem's future margins?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
